Status:
TERMINATED
Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®
Lead Sponsor:
PiLeJe
Collaborating Sponsors:
BioFortis
Conditions:
Vaginal Candidiasis
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
Vulvovaginal candidiasis (VVC) is a common infection among women that is associated with considerable morbidity and health-care cost. 75% of women will suffer of Candida infection for at least one tim...
Eligibility Criteria
Inclusion
- women
- 18-65 years
- suffering from 4 or more episodes of VVC during the 1 year prior to the survey
- all participants must be symptomatic with a microbiological proof of infection with candida albicans
Exclusion
- Pregnancy, lactation being
- HIV infection, chemotherapy or illness serious enough to induce an immune deficiency. A diabetic patient will not be systematically excluded;
- Vulvo-vaginitis and / or cervicitis specific, defined in a bacteriological examination by the presence of herpes virus, gonorrhea or chlamydia;
- Bacterial Vaginosis or Trichomonas;
- Use of vaginal probiotics in the months before inclusion;
- Cure of probiotics in the months preceding the inclusion;
- Contraindication to Gynopévaryl LP
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT00915629
Start Date
June 1 2009
End Date
July 1 2010
Last Update
April 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pileje
Paris, France, 75015